Not Yet RecruitingNot Applicable

Psychometric Hepatic Encephalopathy Score in Prediction of Minimal Hepatic Encephalopathy in Compensated Cirrhotic Patients

150 participantsStarted 2025-12-01

Plain-language summary

Minimal hepatic encephalopathy (MHE) is a covert form of hepatic encephalopathy associated with cognitive and psychomotor impairment in patients with compensated liver cirrhosis. Early detection of MHE is crucial to prevent progression to overt encephalopathy. The Psychometric Hepatic Encephalopathy Score (PHES) is a validated neuropsychological test battery for diagnosing MHE. This study aims to screen for MHE among compensated cirrhotic patients using PHES and to compare performance with healthy matched controls.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18-70 years.
✓. Diagnosed compensated liver cirrhosis, regardless of etiology.
✓. Able to read and write.
✓. Adequate vision, hearing, and physical ability to perform the PHES tests.
✓. Age 18-70 years.
✓. No chronic medical, neurological, psychiatric, renal, or cardiac disease.
✓. Able to read and write.
✓. Adequate cognition, hearing, vision, and physical ability.

Exclusion criteria

✕. Chronic liver disease.
✕. Neuropsychiatric illness.
✕. Use of psychoactive medications.
✕. Illiteracy.

What they're measuring

Detection rate of minimal hepatic encephalopathy using PHES

Timeframe: Baseline assessment

Trial details

NCT IDNCT07272707

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09-01

Contact for this trial

Sara Sabry, Resident doctor

01005344254 sara_sabry_post@med.sohag.edu.eg

View on ClinicalTrials.gov More Minimal Hepatic Encephalopathy trials